Pancreatic Cancer Research

ResearcherPusan National UniversityActive in the last 2 years

Dong Uk Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7208-7753; OpenAlex author ID A5091134003. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers

Papers 15

  1. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  2. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
  3. A Preliminary Study of a Prototype Cryoablation Needle on Porcine Livers for Pancreatic Cancer Treatment. Co-author DOI 10.3390/jcm13174998↗
  4. Clinical significance of C-reactive protein-to-prealbumin ratio in predicting early recurrence in resectable pancreatic cancer. Co-author DOI 10.14216/kjco.23003↗
  5. Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer? Co-author DOI 10.5009/gnl210585.e↗
  6. Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer? Co-author DOI 10.5009/gnl210585↗
  7. Circulating Tumor Cell Clusters Are Cloaked with Platelets and Correlate with Poor Prognosis in Unresectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13215272↗
  8. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. First author DOI 10.12998/wjcc.v8.i17.3718↗
  9. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. First author DOI 10.12998/wjcc.v8.i18.4022↗
  10. Does the Cytogenetic Analysis Using Fluorescence In Situ Hybridization Improve the Preoperative Diagnostic Accuracy of Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.5009/gnl20192↗
  11. Genetic Analysis Can Surrogate the Treatment Strategies in Patients with Pancreatic Cancer. Co-author DOI 10.5009/gnl19319↗
  12. [Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20]. Co-author DOI 10.4166/kjg.2018.71.4.244↗
  13. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  14. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors]. First author DOI 10.4166/kjg.2014.64.6.356↗
  15. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who hav… Co-author DOI 10.1159/000356158↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sung Yong Han · 4 shared papers, 2020–2024 · strength 0.67
  2. Seung Baek Hong · 3 shared papers, 2020–2023 · strength 0.43
  3. Hyung Il Seo · 3 shared papers, 2020–2023 · strength 0.43
  4. Nam Kyung Lee · 3 shared papers, 2020–2023 · strength 0.43
  5. Si Young Song · 3 shared papers, 2017–2024 · strength 0.38
  6. Ho Gak Kim · 3 shared papers, 2017–2024 · strength 0.38
  7. Ho Soon Choi · 3 shared papers, 2017–2024 · strength 0.38
  8. Yong‐Tae Kim · 3 shared papers, 2017–2024 · strength 0.38
  9. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  10. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  11. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33
  12. Mi‐Suk Park · 2 shared papers, 2024 · strength 0.33
  13. Hong Sik Lee · 2 shared papers, 2024 · strength 0.33
  14. Y. Choi · 2 shared papers, 2024 · strength 0.33
  15. Jung Hyun Jo · 2 shared papers, 2024 · strength 0.33
  16. Hyungsik Roger Moon · 2 shared papers, 2024 · strength 0.33
  17. Eun Kwang Choi · 2 shared papers, 2024 · strength 0.33
  18. Seung Ok Lee · 2 shared papers, 2024 · strength 0.33
  19. Young Woo Choi · 2 shared papers, 2024 · strength 0.33
  20. Woo Jin Lee · 2 shared papers, 2024 · strength 0.33
  21. Gun-Ho Kim · 1 shared paper, 2024 · strength 0.24
  22. Hyunjoon Son · 1 shared paper, 2024 · strength 0.24
  23. Byeong Gwan Noh · 1 shared paper, 2023 · strength 0.18
  24. Chae Hwa Kwon · 1 shared paper, 2023 · strength 0.18
  25. Kwang Hyuck Lee · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.